Treatment and prognostic factors in acute myeloid leukaemia

The treatment of acute myeloid leukaemia (AML) has evolved considerably over the past decade. While induction therapy appears to have been almost standardized, there continues to be an ongoing debate and controversy regarding the best form of post-remission therapy. Furthermore, attempts are being made to identify patients at particular risk of relapse to enable appropriate selection of best induction and post-remission therapies. New concepts include the use of growth factors, immunotherapy and MDR modulation at various stages in the treatment of AML, and all of these will be discussed in this chapter.